AJAlan G. Japp

Alan G. Japp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alan G. Japp has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • David E. Newby

    British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, UK

    3 shared publications
  • Ian L. Megson

    Free Radical Research Facility, Division of Biomedical Sciences, University of the Highlands & Islands, Inverness, UK

    2 shared publications
  • A.D. Flapan

    From the Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, UK (A.G.J., N.L.C., N.v.G., J.M., A.D.F.); Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK (G.B., N.R.J., M.A.D., D.E.N.); and Department of Diabetes & Cardiovascular Science, UHI Millennium Institute, Inverness, UK (J.A., I.L.M.).

    1 shared publication
  • Andrew D. Flapan

    1 shared publication
  • Arie Katz

    Wyeth Research, Collegeville, PA

    1 shared publication
  • D.E. Newby

    From the Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, UK (A.G.J., N.L.C., N.v.G., J.M., A.D.F.); Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK (G.B., N.R.J., M.A.D., D.E.N.); and Department of Diabetes & Cardiovascular Science, UHI Millennium Institute, Inverness, UK (J.A., I.L.M.).

    1 shared publication

Latest Publications

  • Remodeling in heart failure: from the left ventricle to service delivery

    by Alan G Japp, Stephen J Pettit

    Over the past three decades, advances in our understanding of heart failure pathophysiology have spurred the development of effective therapies for patients with heart failure and led to improved clinical outcomes. Further progress now requires increased provision of existing evidence-based therapies together with continued exploration of underlying pathogenic mechanisms and therapeutic targets. This was reflected at the 2012 Annual Autumn Meeting of the British Society for Heart Failure, attended by over 500 delegates from around the world with strong representation from all heart failure disciplines. The conference included a dedicated session on 'cardiac remodeling in left ventricular systolic dysfunction' as well as presentations on the latest evidence-based therapies in heart failure and aspects of service delivery within the UK.


  • Open Access

    Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans

    by Alan G. Japp, Raj Chelliah, Laura Tattersall, Ninian N. Lang, Xu Meng, Kathleen Weisel, Arie Katz, David Burt, Keith A. A. Fox, Giora Z. Feuerstein, et al.

    Background: Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression ofP‐selectin on activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.P‐selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the novelP‐selectin antagonistPSI‐697 on platelet–monocyte aggregate formation in humans.Methods and Results: In a double‐blind, randomized, placebo‐controlled crossover study, healthy smokers were randomized to receive either oralPSI‐697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects receiving bothPSI‐697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the presence and absence of thrombin receptor‐activating peptide (TRAP; 0.1 to 1.0 μm/L). Theex vivoaddition ofTRAPcaused a concentration‐dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (PPP>0.05).P‐selectin‐blocking antibody (CLB‐Thromb6), but notPSI‐697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).Conclusions: The novel small‐moleculeP‐selectin antagonistPSI‐697 did not inhibit basal or stimulated platelet–monocyte aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.Clinical Trial Registration: URL:http://EudraCT.ema.europa.euUnique identifier: 2007‐005695‐14.


  • Open Access

    Acute Cardiovascular Effects of Apelin in Humans

    by A.G. Japp, N.L. Cruden, G. Barnes, N. van Gemeren, J. Mathews, J. Adamson, N.R. Johnston, M.A. Denvir, I.L. Megson, A.D. Flapan, et al.

    Background— Apelin, the endogenous ligand for the novel G protein–coupled receptor APJ, has major cardiovascular effects in preclinical models. The study objectives were to establish the effects of acute apelin administration on peripheral, cardiac, and systemic hemodynamic variables in healthy volunteers and patients with heart failure. Methods and Results— Eighteen patients with New York Heart Association class II to III chronic heart failure, 6 patients undergoing diagnostic coronary angiography, and 26 healthy volunteers participated in a series of randomized, double-blind, placebo-controlled studies. Measurements of forearm blood flow, coronary blood flow, left ventricular pressure, and cardiac output were made by venous occlusion plethysmography, Doppler flow wire and quantitative coronary angiography, pressure wire, and thoracic bioimpedance, respectively. Intrabrachial infusions of (Pyr 1 )apelin-13, acetylcholine, and sodium nitroprusside caused forearm vasodilatation in patients and control subjects (all P P =0.01) but not apelin ( P =0.3) or sodium nitroprusside ( P =0.9) was attenuated in patients with heart failure. Intracoronary bolus of apelin-36 increased coronary blood flow and the maximum rate of rise in left ventricular pressure and reduced peak and end-diastolic left ventricular pressures (all P 1 )apelin-13 (30 to 300 nmol/min) increased cardiac index and lowered mean arterial pressure and peripheral vascular resistance in patients and healthy control subjects (all P P Conclusions— Acute apelin administration in humans causes peripheral and coronary vasodilatation and increases cardiac output. APJ agonism represents a novel potential therapeutic target for patients with heart failure.


  • Vascular Effects of Apelin In Vivo in Man

    by Alan G. Japp, Nicholas L. Cruden, David A.B. Amer, Vivienne K.Y. Li, Ewan B. Goudie, Neil R. Johnston, Sushma Sharma, Ilene Neilson, David J. Webb, Ian L. Megson, et al.


  • The apelin–APJ system in heart failure

    by Alan G. Japp, David E. Newby